Oxymetazoline HClAlpha-1/alpha-2 agonist CAS# 2315-02-8 |
- A-867744
Catalog No.:BCC1324
CAS No.:1000279-69-5
- Rocuronium Bromide
Catalog No.:BCC1068
CAS No.:119302-91-9
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 2315-02-8 | SDF | Download SDF |
PubChem ID | 66259 | Appearance | Powder |
Formula | C16H25ClN2O | M.Wt | 296.84 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in water | ||
Chemical Name | 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol;hydrochloride | ||
SMILES | CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C.Cl | ||
Standard InChIKey | BEEDODBODQVSIM-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H24N2O.ClH/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14;/h8,19H,6-7,9H2,1-5H3,(H,17,18);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Partial α2A adrenoceptor agonist and α1A agonist. Agonist/antagonist activity at 5-HT receptors. |
Oxymetazoline HCl Dilution Calculator
Oxymetazoline HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.3688 mL | 16.8441 mL | 33.6882 mL | 67.3764 mL | 84.2205 mL |
5 mM | 0.6738 mL | 3.3688 mL | 6.7376 mL | 13.4753 mL | 16.8441 mL |
10 mM | 0.3369 mL | 1.6844 mL | 3.3688 mL | 6.7376 mL | 8.422 mL |
50 mM | 0.0674 mL | 0.3369 mL | 0.6738 mL | 1.3475 mL | 1.6844 mL |
100 mM | 0.0337 mL | 0.1684 mL | 0.3369 mL | 0.6738 mL | 0.8422 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Oxymetazoline Hydrochloride is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant.Oxymetazoline is a selective alpha-1 agonist and partial alpha-2 agonist topical decongestant, used in the form of Oxymetazoline hydrochloride. It
- Pentoxyverine Citrate
Catalog No.:BCC4697
CAS No.:23142-01-0
- Vincosamide
Catalog No.:BCN5081
CAS No.:23141-27-7
- Strictosamide
Catalog No.:BCN5080
CAS No.:23141-25-5
- Physalin B
Catalog No.:BCN7921
CAS No.:23133-56-4
- Heveaflavone
Catalog No.:BCN5079
CAS No.:23132-13-0
- Tectorigenin 7-O-xylosylglucoside
Catalog No.:BCN2903
CAS No.:231288-19-0
- 6'-O-xylosyl-glycitin
Catalog No.:BCN8169
CAS No.:231288-18-9
- Mudanpioside H
Catalog No.:BCC9049
CAS No.:231280-71-0
- 5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-carbaldehyde
Catalog No.:BCC8719
CAS No.:231278-84-5
- N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine
Catalog No.:BCC9068
CAS No.:231278-20-9
- Lapatinib
Catalog No.:BCC3633
CAS No.:231277-92-2
- Methylxanthoxylin
Catalog No.:BCC8212
CAS No.:23121-32-6
- H-Glu(OMe)-OMe.HCl
Catalog No.:BCC2932
CAS No.:23150-65-4
- 3,4-Dimethoxycinnamic acid
Catalog No.:BCN5040
CAS No.:2316-26-9
- Pyrolatin
Catalog No.:BCN8439
CAS No.:23176-70-7
- Nervosine
Catalog No.:BCN2012
CAS No.:23179-26-2
- Songoramine
Catalog No.:BCN6474
CAS No.:23179-78-4
- Senkirkine
Catalog No.:BCN2136
CAS No.:2318-18-5
- Simiarenone
Catalog No.:BCN5082
CAS No.:2318-78-7
- Paeoniflorin
Catalog No.:BCN6301
CAS No.:23180-57-6
- Columbianetin acetate
Catalog No.:BCN2652
CAS No.:23180-65-6
- (1R,2S)-2-Amino-1,2-diphenylethanol
Catalog No.:BCC8382
CAS No.:23190-16-1
- Matairesinoside
Catalog No.:BCN7583
CAS No.:23202-85-9
- Ifenprodil hemitartrate
Catalog No.:BCC6688
CAS No.:23210-56-2
Cardiovascular effects of oxymetazoline and UK14,304 in conscious and pithed rats.[Pubmed:9140707]
Clin Exp Hypertens. 1997 May;19(4):445-60.
Relatively selective alpha 2-adrenoceptor agonists have proven useful in a variety of therapeutic situations including hypertension, glaucoma and withdrawal from opiate addiction. In particular, oxymetazoline (OXY) and UK14,304 (UK) have been used in subclassifying alpha 2-adrenoceptors and imidazoline receptors. We evaluated the cardiovascular effects of OXY and UK in conscious and pithed rats in the presence and absence of efaroxan (EFA), idazoxan (IDA) and rauwolscine (RAU). Both OXY or UK (1, 5 and 10 micrograms/kg, i.v.) increased blood pressure (BP) and reduced heart rate (HR) in conscious rats. In pithed rats, OXY and UK each increased BP to a greater extent than that observed in conscious rats, but HR was not affected. BP increases following sympathetic nerve stimulation in the pithed rats were not affected by OXY but were reduced by UK at 0.1 Hz and 0.3 Hz. HR responses to nerve stimulation in pithed rats were reduced after OXY at all frequencies, but only at 0.1 Hz following UK. EFA, IDA and RAU inhibited the pressor responses of UK, with EFA being most potent. OXY-induced pressor responses were inhibited by all three antagonists, RAU being the least potent. HR responses to either OXY or UK were not affected by the antagonists. Taken together, the data suggest that: 1) alpha 2-adrenoceptors contribute less to the vascular response to OXY than to UK based upon the antagonistic effect of RAU; 2) prejunctional I1 receptors maybe more prevalent in the heart than in vascular tissue based upon the response to OXY in pithed rats. Thus, the heterogeneity among receptors mediating cardiac and vascular responses are complex.
Selectivity of the imidazoline alpha-adrenoceptor agonists (oxymetazoline and cirazoline) for human cloned alpha 1-adrenoceptor subtypes.[Pubmed:8564227]
Br J Pharmacol. 1995 Sep;116(1):1611-8.
1. To investigate the structure-activity relationships of alpha-adrenoceptor agonists for the alpha 1-adrenoceptor subtypes, we have compared the imidazoline class of compounds, oxymetazoline and cirazoline, with the phenethylamine, noradrenaline, in their affinities and also in their intrinsic activities in Chinese hamster ovary (CHO) cells stably expressing the cloned human alpha 1-adrenoceptor subtypes (alpha 1a-, alpha 1b-, and alpha 1d-subtypes). 2. Radioligand binding studies with [125I]-HEAT showed that cirazoline and oxymetazoline had higher affinities at alpha 1a-subtype than at alpha 1b- and alpha 1d-subtypes, while noradrenaline had higher affinity at the alpha 1d-subtype than at alpha 1a- and alpha 1b-subtypes. 3. In functional studies, cirazoline caused transients of cytosolic Ca2+ concentrations ([Ca2+]i response) in a concentration-dependent manner and developed a maximal response similar to that to noradrenaline in CHO cells expressing the alpha 1a-subtype, while it acted as a partial agonist at alpha 1b- and alpha 1d-adrenoceptors. Oxymetazoline, on the other hand, was a weak agonist at alpha 1a-adrenoceptors, and has no intrinsic activity at the other subtypes. 4. Using the phenoxybenzamine inactivation method, the relationships between receptor occupancy and noradrenaline-induced [Ca2+]i response for alpha 1a- and alpha 1d-subtypes were found to be linear, whereas it was moderately hyperbolic for the alpha 1b-subtype, indicating the absence of receptor reserves in CHO cells expressing alpha 1a- and alpha 1d-subtypes while there exists a small receptor reserve for CHO cells expressing the alpha 1b-subtype. 5 In summary, our data obtained in cells exclusively expressing a single receptor subtype support the idea that the relative role of agonist affinity and intrinsic activity may vary depending on the subtype of alphal-adrenoceptor.
Interaction of the alpha-adrenoceptor agonist oxymetazoline with serotonin 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors.[Pubmed:1678720]
Eur J Pharmacol. 1991 Apr 17;196(2):213-6.
Oxymetazoline was recognized with nanomolar affinity by 5-HT1A, 5-HT1B and 5-HT1D binding sites and mimicked the effects of 5-hydroxytryptamine with about the same potency and intrinsic activity as the endogenous amine in the corresponding functional tests. At 5-HT1C receptors, oxymetazoline behaved as a mixed agonist-antagonist. Clonidine had minimal activity. Methiothepin antagonized the effects of oxymetazoline (7.4 less than pKB less than 8.8). Thus, oxymetazoline is a full and potent agonist at 5-HT1A, 5-HT1B and 5-HT1D receptors and a partial agonist at 5-HT1C receptors.